Emergent BioSolutions (Emergent BioSolutions) Debt-to-Equity : 1.33 (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Emergent BioSolutions Debt-to-Equity?

Emergent BioSolutions's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $414 Mil. Emergent BioSolutions's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $447 Mil. Emergent BioSolutions's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $649 Mil. Emergent BioSolutions's debt to equity for the quarter that ended in Dec. 2023 was 1.32.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Emergent BioSolutions's Debt-to-Equity or its related term are showing as below:

EBS' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.56 Max: 1.33
Current: 1.33

During the past 13 years, the highest Debt-to-Equity Ratio of Emergent BioSolutions was 1.33. The lowest was 0.02. And the median was 0.56.

EBS's Debt-to-Equity is ranked worse than
91.59% of 856 companies
in the Drug Manufacturers industry
Industry Median: 0.285 vs EBS: 1.33

Emergent BioSolutions Debt-to-Equity Historical Data

The historical data trend for Emergent BioSolutions's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions Debt-to-Equity Chart

Emergent BioSolutions Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.75

0.61

0.52

1.01

1.33

Emergent BioSolutions Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															1.01	1.16	0.94	1.24	1.33

Competitive Comparison of Emergent BioSolutions's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emergent BioSolutions's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's Debt-to-Equity falls into.

Emergent BioSolutions Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Emergent BioSolutions's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(413.7	+	446.5)	/	649.3
	=	1.32

Emergent BioSolutions's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(413.7	+	446.5)	/	649.3
	=	1.32

Emergent BioSolutions (NYSE:EBS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Emergent BioSolutions Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Emergent BioSolutions (Emergent BioSolutions) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (NYSE:EBS) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ER4:Germany ER4:Germany

Address

400 Professional Drive, Suite 400, Gaithersburg, MD, USA, 20879

Website

https://www.emergentbiosolutions.com

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.

Executives

Neal Franklin Fowler	director	C/O EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Donald W Degolyer	director	400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
William Hartzel	officer: SVP, Bioservices	400 PROFESSIONAL DRIVE, STE. 400, GAITHERSBURG MD 20879
Miller H Haywood Iii	officer: Interim CEO	EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Kathryn C Zoon	director	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Paul Anthony Williams	officer: SVP, Products Business	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Ronald Richard	director	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Sujata Tyagi Dayal	director	C/O BIOMET, INC., P.O. BOX 587, WARSAW IN 46581-0587
Keith Katkin	director	C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Glessner Coleen	officer: EVP, Quality & Ethics, and CPL	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Jennifer Lynne Fox	officer: EVP, Ext Aff, GC, Corp Sec	400 PROFESSIONAL DRIVE, GAITHERSBURG MD 20879
Richard S Lindahl	officer: EVP, Chief Financial Officer	NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191
Sue Bailey	director	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20850
Adam Havey	officer: EVP, BioDefense Division	2273 RESEARCH BLVD SUITE 400, ROCKVILLE MD 20853
Robert Kramer	officer: Interim, EVP, BioSciences	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850